← Leaderboards
Rosa Ana Risques
University Of Washington
$5,263,361
Attributed
$5,263,361
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $614.9K · FY2009–25$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,263,361 · 4
By mechanism
R01$4,227,127 · 2
K07$664,200 · 1
R21$372,034 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Washington
Same institution · by research overlap
- Sara R. Curran$1,977,637
- Steven N. Austad$17,360,109
- Matt Kaeberlein$21,041,861
- Garret D. Stuber$15,138,851
- Brian K Kennedy$17,711,378
Others in their field
Top investigators on “High Risk”
- Lawrence Corey · Fred Hutchinson Cancer Center$561,333,990
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$424,554,257
- Wafaa M. El-Sadr · Columbia University Health Sciences$337,188,987
- Gary D Acton · University Of California-Davis$320,373,312
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$303,724,352
Research focus
High RiskSamplingMalignant NeoplasmsLesionBiopsyTumorigenesisDetectionHistologicCoupledPreventTissuesLifeNormal Tissue MorphologyNeoplasticProteinsCellsOverexpressionMutantMutationClustered Regularly Interspaced Short Palindromic RepeatsMammalian OviductsGenetic Predisposition To DiseaseFrequenciesGerm-Line Mutation
Grant awards (20)
Understanding the role of TP53 mutation in genetic susceptibility to ovarian cancer$509,276
R01 · FY2025 · CA · contact PI
Understanding the role of TP53 mutation in genetic susceptibility to ovarian cancer$105,672
R01 · FY2025 · CA · contact PI
Understanding the role of TP53 mutation in genetic susceptibility to ovarian cancer$483,680
R01 · FY2024 · CA · contact PI
Understanding the role of TP53 mutation in genetic susceptibility to ovarian cancer$100,191
R01 · FY2024 · CA · contact PI
Understanding the role of TP53 mutation in genetic susceptibility to ovarian cancer$512,534
R01 · FY2023 · CA · contact PI
Understanding the role of TP53 mutation in genetic susceptibility to ovarian cancer$91,527
R01 · FY2023 · CA · contact PI
Understanding the role of TP53 mutation in genetic susceptibility to ovarian cancer$517,103
R01 · FY2022 · CA · contact PI
Understanding the role of TP53 mutation in genetic susceptibility to ovarian cancer$528,617
R01 · FY2021 · CA · contact PI
Evaluation of TP53 mutations in non-cancerous tissue as novel biomarkers of ovarian cancer risk.$202,928
R21 · FY2020 · CA · contact PI
Evaluation of TP53 mutations in non-cancerous tissue as novel biomarkers of ovarian cancer risk.$169,106
R21 · FY2019 · CA · contact PI
Mitochondrial biomarkers for early detection of cancer in ulcerative colitis$256,470
R01 · FY2018 · CA · contact PI
Mitochondrial biomarkers for early detection of cancer in ulcerative colitis$288,529
R01 · FY2017 · CA · contact PI
Mitochondrial biomarkers for early detection of cancer in ulcerative colitis$320,588
R01 · FY2016 · CA · contact PI
Mitochondrial biomarkers for early detection of cancer in ulcerative colitis$256,470
R01 · FY2015 · CA · contact PI
Mitochondrial biomarkers for early detection of cancer in ulcerative colitis$256,470
R01 · FY2014 · CA · contact PI
Senescence biomarkers for cancer prevention in ulcerative colitis$132,840
K07 · FY2013 · CA · contact PI
Senescence biomarkers for cancer prevention in ulcerative colitis$132,840
K07 · FY2012 · CA · contact PI
Senescence biomarkers for cancer prevention in ulcerative colitis$132,840
K07 · FY2011 · CA · contact PI
Senescence biomarkers for cancer prevention in ulcerative colitis$132,840
K07 · FY2010 · CA · contact PI
Senescence biomarkers for cancer prevention in ulcerative colitis$132,840
K07 · FY2009 · CA · contact PI